Study identifies why DOCK8 deficiency drives severe food allergies
A study in the Journal of Experimental Medicine found that DOCK8 deficiency drives severe food allergies by expanding Tfh13 cells and reducing regulatory T-cells. The findings help explain why DOCK8 mutations, but not STAT3 mutations alone, consistently lead to elevated food-specific IgE and clinically significant reactions.
A new study has shed light on why patients with certain rare immune disorders develop severe, food-triggered allergic reactions while others with similar diagnoses do not. The findings, published in the Journal of Experimental Medicine, identify a key reason for the difference between loss-of-function mutations in the DOCK8 gene and dominant-negative mutations in STAT3. While both disorders fall under hyper-IgE syndrome, only DOCK8 deficiency consistently leads to elevated food-specific IgE and clinically significant allergic reactions.
The new study found that the two disorders affect a specialized group of immune cells in very different ways. Previous research in mouse models showed that DOCK8 normally acts as a brake on Tfh13 cells, a subset of helper T-cells known to drive the production of anaphylactic IgE. The new findings reveal that DOCK8 helps activate STAT3, a transcription factor that in turn suppresses GATA3, a driver of Tfh13 cell development. Without DOCK8, STAT3 activity falters, allowing GATA3 and Tfh13 cells to expand.
However, only patients with DOCK8 deficiency, not those with STAT3 mutations, showed elevated levels of Tfh13 cells in their blood. To probe deeper, investigators engineered mice lacking either DOCK8 or STAT3 specifically in T-cells. When the animals were orally exposed to peanut alongside an immune-boosting drug, both groups produced high levels of peanut-specific IgE and Tfh13 cells.
During adjuvant-free oral exposure, which more closely mimics how humans encounter food allergens in everyday life, the two models diverged dramatically. Mice lacking DOCK8 in T-cells developed strong peanut-specific IgE responses and abundant Tfh13 cells, but mice lacking STAT3 did not.
The key difference turned out to be regulatory T-cells (Tregs), which normally work to suppress allergic sensitization. DOCK8-deficient mice showed reduced levels of Foxp3+ Tregs, while STAT3-deficient mice retained them. When investigators intentionally depleted Tregs in the STAT3-deficient mice, Tfh13 cells emerged even without an adjuvant, mirroring what happens naturally in DOCK8 deficiency.
The findings suggest that two immune-system failures together set the stage for severe food allergies: loss of DOCK8-STAT3 signaling, which removes restraints on Tfh13 cells, and impaired Treg function, which removes the immune system’s tolerance-promoting safeguards. Because DOCK8 deficiency affects both pathways, patients with this mutation are far more likely to develop life-threatening food allergies than those with STAT3 mutations alone.
The study identifies Tfh13 cells as a potentially important biomarker for severe food allergy risk, including in patients with rare immunodeficiencies. It also points toward therapeutic strategies that could someday reduce allergic responses by restoring the DOCK8-STAT3-GATA3 balance or strengthening regulatory T-cells.